Short of the ABPA Line: Does a Failed Diagnostic Threshold Change What Gets Prescribed
A woman with severe asthma and a strong fungal allergic sensitization doesn't meet the full diagnostic criteria for ABPA. Whether that distinction should change her therapy — or whether it's a diagnostic label without a therapeutic consequence — is the actual argument.
M.T., a 51-year-old high school choir director, has spent three decades teaching in a building with a basement rehearsal room she has long suspected of hidden water damage behind the risers. Her asthma, diagnosed in her thirties, has been steadily worsening over the past two years despite escalating inhaled therapy, and she now uses her rescue inhaler most days rather than the occasional-flare pattern she managed for most of her career.
Her allergist ordered the full ABPA workup given how strongly fungal sensitization fit her history, and the results are genuinely mixed rather than clean in either direction. Aspergillus fumigatus-specific IgE came back strongly positive, and her total IgE of 620 IU/mL is elevated — but it falls short of the roughly 1,000 IU/mL threshold the ISHAM working group's criteria use, she has no serum Aspergillus precipitins, and her HRCT shows no central bronchiectasis, only the airway-wall thickening already expected from longstanding severe asthma. By the numbers, she has severe asthma with fungal sensitization, not ABPA. What she does not have is a clean, quiet clinical course: two hospitalizations in the past year and a quality of life that has narrowed considerably, in a patient whose actual diagnostic label technically falls short of a diagnosis that would otherwise steer the room toward more aggressive antifungal therapy.
She has no other lung disease, no smoking history, and no prior hospitalization before the last year — the deterioration is recent and real, not a longstanding baseline she has simply learned to live with. She has, at her own initiative, already asked the school district to investigate the rehearsal room; nothing has been confirmed yet, and abatement, if it happens at all, is not something she expects to see resolved on any timeline relevant to today's decision. She has led that choir program for most of her career and has quietly started wondering, out loud to her allergist if not yet to her own department, whether she can keep doing the parts of the job that put her back in that basement room at all.
Case conference, severe asthma versus fungal disease
The ISHAM threshold is a diagnostic convention, not a biological cliff. Denning's original SAFS description and the later FAST trial treated fungal sensitization in severe asthma as a therapeutic target in its own right, independent of whether a patient crosses the full ABPA line. FAST randomized SAFS patients — her exact category — to itraconazole or placebo and found a real improvement in quality of life, which is precisely what's declined most sharply for her.
I'd read that same trial more cautiously before committing her to months of azole therapy. FAST moved quality-of-life scores, its primary endpoint, but respiratory function was a secondary endpoint that didn't move, and exacerbation rate wasn't among its endpoints at all — so on the one outcome actually driving her two hospitalizations this year, the trial is silent rather than reassuring. An intervention with real hepatotoxicity risk and a documented interaction burden shouldn't be adopted on a symptom-score endpoint alone when the outcome she's actually suffering from wasn't the one that moved.
You're not wrong that FAST is the closest trial we have to her exact phenotype — the disagreement is about whether a quality-of-life benefit alone justifies it, not about whether the trial applies to her.
Both of you are reading FAST correctly on its own terms — the disagreement is really about what she needs most right now, and I'd escalate her severe-asthma biologic pathway before reaching for an antifungal whose own trial gave a mixed signal on the outcomes that matter most to her. Her IgE and clinical severity already meet standard criteria for anti-IgE therapy on the severe-asthma pathway alone, independent of the ABPA/SAFS question entirely.
Itraconazole isn't wrong to hold in reserve — if omalizumab doesn't touch her hospitalization rate, FAST is real evidence for trying it next. But starting with the drug that matches a diagnostic label she doesn't fully carry, ahead of one she unambiguously qualifies for, gets the sequencing backward.
Agreed: omalizumab initiated today on standard severe-allergic-asthma criteria, with hospitalization frequency and rescue inhaler use tracked explicitly as the outcomes that matter, given FAST's mixed result on those specific measures.
Not agreed: how long to wait before adding itraconazole if omalizumab helps her symptoms without reducing hospitalizations. The allergist would add it as soon as any gap in benefit appears; the pulmonologist wants a full four-to-six-month trial of omalizumab alone first, given that stacking interventions early would make it impossible to know which drug is doing the work if she does improve.